# Complete Reference List with PMIDs

**Format:** Vancouver style (numbered, as used in manuscript)  
**Status:** ✅ Complete with all PMIDs extracted

---

## References (Vancouver Style)

1. Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17(12):e542-e551. PMID: 27733244. doi: 10.1016/S1470-2045(16)30406-5.

2. Topalian SL, Hodi FS, Brahmer JR, et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol. 2019;5(10):1411-1420. PMID: 31343660. doi: 10.1001/jamaoncol.2019.2187.

3. Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202-206. PMID: 30643254. doi: 10.1038/s41588-018-0312-8.

4. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409-413. PMID: 28596308. doi: 10.1126/science.aan6733.

5. Riaz N, Havel JJ, Makarov V, et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017;171(4):934-949.e16. PMID: 29033130. doi: 10.1016/j.cell.2017.10.028.

6. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568-571. PMID: 25428505. doi: 10.1038/nature13954.

---

## Additional References (For Future Expansion)

7. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093-2104. PMID: 29658845. doi: 10.1056/NEJMoa1801946.

8. Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500-2501. PMID: 29262275. doi: 10.1056/NEJMc1713444.

9. Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930-2940. PMID: 28650338. doi: 10.1172/JCI91190.

10. Hugo W, Zaretsky JM, Sun L, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35-44. PMID: 26997480. doi: 10.1016/j.cell.2016.02.065.

---

## Dataset Citations

- **GSE91061**: Riaz N, Havel JJ, Makarov V, et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017;171(4):934-949.e16. PMID: 29033130. GEO Accession: GSE91061. Available at: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE91061

- **GSE179994**: [To be added when external validation is complete]

---

## Software Citations

- **scikit-learn**: Pedregosa F, Varoquaux G, Gramfort A, et al. Scikit-learn: Machine Learning in Python. J Mach Learn Res. 2011;12:2825-2830.

- **scipy**: Virtanen P, Gommers R, Oliphant TE, et al. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat Methods. 2020;17(3):261-272. PMID: 32015543. doi: 10.1038/s41592-019-0686-2.

- **pandas**: McKinney W. Data structures for statistical computing in python. Proceedings of the 9th Python in Science Conference. 2010;445:51-56.

---

**Total References:** 6 (main manuscript) + 4 (additional) = 10 references  
**All PMIDs Verified:** ✅  
**DOIs Included:** ✅  
**Format:** Vancouver (numbered) style
